← Oncology Approval Tracker

FDA DECISION ·

Keytruda

pembrolizumab · Merck

FDA approvalIndication revisionEsophageal and proximal gastroesophageal junction cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Limits pembrolizumab with platinum and fluoropyrimidine chemotherapy in locally advanced or metastatic esophageal or qualifying GEJ carcinoma that cannot be treated with resection or definitive chemoradiation to tumors with PD-L1 CPS of at least 1.

LAMPGEN ANALYSIS

Why it matters

The first-line combination label now requires PD-L1 expression; the separate post-systemic monotherapy indication retains its higher threshold.

What research teams should watch

Confirm the anatomic site and PD-L1 score and apply the threshold specific to the intended regimen.

PRIMARY RECORDS

Sources